Kings Point Capital Management’s Charles River Laboratories CRL Stock Holding History

Kings Point Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$13.8M	Buy	48,448 +1,639	+4%	+$505K	1.2%	34
2021 Q4	$17.6M	Buy	46,809 +1,992	+4%	+$774K	1.44%	24
2021 Q3	$18.5M	Sell	44,817 -13,357	-23%	-$5.55M	1.64%	16
2021 Q2	$21.5M	Sell	58,174 -1,255	-2%	-$419K	1.95%	9
2021 Q1	$17.2M	Buy	59,429 +240	+0.4%	+$66.7K	1.7%	12
2020 Q4	$14.8M	Sell	59,189 -143	-0.2%	-$34.1K	1.58%	13
2020 Q3	$13.4M	Buy	59,332 +1,720	+3%	+$357K	1.68%	12
2020 Q2	$10M	Buy	57,612 +687	+1%	+$110K	1.46%	19
2020 Q1	$7.18M	Buy	56,925 +29,407	+107%	+$4.41M	1.27%	29
2019 Q4	$4.2M	Buy	27,518 +3,949	+17%	+$547K	0.62%	56
2019 Q3	$3.12M	Buy	23,569 +23,492	+30,509%	+$3.15M	0.53%	61
2019 Q2	$11K	Buy	+77	New	+$10.4K	﹤0.01%	411

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Kings Point Capital Management's CRL Position: Q1 2022 in Review

Kings Point Capital Management increased its Charles River Laboratories (CRL) stake by 3.5% in Q1 2022, buying an estimated $505K and bringing the position to 48,448 shares worth $13.8M. The position accounts for 1.2% of the portfolio, ranked #34.

Kings Point Capital Management first reported a position in CRL in Q2 2019 and has held it in 12 quarters since. The position peaked at $21.5M in Q2 2021. 644 funds tracked by Wall St. Rank hold CRL as of Q1 2022.

Kings Point Capital Management held 48,448 shares of Charles River Laboratories worth $13.8M as of Q1 2022.
Kings Point Capital Management bought 1,639 Charles River Laboratories shares in Q1 2022, an estimated $505K.
Charles River Laboratories made up 1.2% of Kings Point Capital Management's portfolio in Q1 2022, its #34 holding.
Kings Point Capital Management first reported a position in Charles River Laboratories in Q2 2019 and has held it in 12 quarters since.
Kings Point Capital Management's Charles River Laboratories position peaked at $21.5M in Q2 2021.
644 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2022.

Based on Kings Point Capital Management's 13F filing for Q1 2022, filed 13 May 2022.